Physician profile
Eric A Weiner
NPI 1982601993
$6,499.09
in general payments reported to CMS, 2019-2025
24 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $195 · 2021: $256 · 2022: $15.88 · 2023: $3,242 · 2024: $571 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,016 · Food and Beverage: $1,453 · Travel and Lodging: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,015.99 |
| Food and Beverage | $1,453.13 |
| Travel and Lodging | $1,001.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,022.44 | 2023 | Da Vinci Surgical System |
| Inspire Medical Systems, INC. | $2,126.03 | 2019-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $181.05 | 2020-2025 | Fasenra, Breztri |
| Harmony Biosciences LLC | $162.92 | 2020-2023 | Wakix |
| Itamar Medical INC | $158.88 | 2024 | Watchpatone |
| Paratek Pharmaceuticals, INC. | $144.80 | 2021 | |
| Abiomed | $129.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $104.66 | 2019-2023 | Xywav |
| Genentech USA, INC. | $102.16 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $75.20 | 2020-2021 | |
| Glaxosmithkline, LLC. | $33.29 | 2019 | |
| Breas Medical, INC. | $31.54 | 2024 | Vivo 45 Ls |
| Lilly USA, LLC | $27.42 | 2025 | Zepbound |
| Ceribell, INC. | $25.26 | 2025 | Pocket Eeg Device |
| Insmed, INC. | $22.27 | 2025 | Brinsupri, Arikayce |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.13 | 2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $21.05 | 2019 | |
| Baxter Healthcare | $20.32 | 2023 | Renal - Acute |
| Allergan, INC. | $16.62 | 2019 | |
| Resmed Corp | $16.38 | 2019 | |
| Sirius Medical Systems | $15.78 | 2024 | Pintuition |
| Pfizer INC. | $13.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.46 | 2021 | |
| Electromed, INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.